Table 4. Multivariable logistic regression models including age, PSA, PSA density, DRE status and CIPC for tumor upstaging, upgrading, unfavorable disease, positive surgical margins and predominant Gleason 4.

	Upstaging
	Continous TT		TT≥300ng/dL TT<300ng/dL
	O.R. [95% C.I.]	p-value	O.R. [95% C.I.]	p-value
Age	0.94 [0.89 to 1]	0,036	0.95 [0.9 to 1]	0,063
PSA (ng/mL)	1.22 [0.93 to 1.6]	0,149	1.15 [0.89 to 1.5]	0,29
PSA Density, 0.1 increase	0.47 [0.14 to 1.62]	0,231	0.45 [0.13 to 1.51]	0,193
Positive DRE	1.31 [0.48 to 3.55]	0,600	1.14 [0.42 to 3.12]	0,798
CIPC	1.05 [1.03 to 1.07]	<0.001	1.05 [1.03 to 1.07]	<0.001
Testosterone, 10 ng/dl increase	0.92 [0.89 to 0.94]	<0.001
Testosterone, <300 ng/dL			11.62 [5.43 to 24.85]	<0.001
AUC, [95% C.I.]	0.84 [0.79 to 0.9]		0.81 [0.75 to 0.88]
Gain in predictive accuracy; % (p-value)	15.2 (<0.001)		12.4 (0.002)
	Upgrading
	Continous TT		TT≥300ng/dL TT<300ng/dL
	O.R. [95% C.I.]	p-value	O.R. [95% C.I.]	p-value
Age	1.01 [0.96 to 1.05]	0,827	1.01 [0.96 to 1.05]	0,791
PSA (ng/mL)	1.02 [0.84 to 1.24]	0,868	1.02 [0.83 to 1.24]	0,87
PSA Density, 0.1 increase	1.07 [0.43 to 2.63]	0,890	0.97 [0.39 to 2.39]	0,945
Positive DRE	1.18 [0.54 to 2.6]	0,674	1.14 [0.51 to 2.53]	0,754
CIPC	1.05 [1.03 to 1.07]	<0.001	1.05 [1.03 to 1.07]	<0.001
Testosterone, 10 ng/dl increase	0.97 [0.96 to 0.99]	0,001
Testosterone, <300 ng/dL			3.6 [1.74 to 7.46]	0,001
AUC, [95% C.I.]	0.73 [0.68 to 0.79]		0.73 [0.68 to 0.79]
Gain in predictive accuracy; % (p-value)	0.1 (0.935)		0.1 (0.922)
	Unfavorable Disease
	Continous TT		TT≥300ng/dL TT<300ng/dL
	O.R. [95% C.I.]	p-value	O.R. [95% C.I.]	p-value
Age	0.95 [0.88 to 1.03]	0,217	0.95 [0.87 to 1.03]	0,197
PSA (ng/mL)	1.29 [0.86 to 1.93]	0,222	1.26 [0.82 to 1.92]	0,287
PSA Density, 0.1 increase	0.14 [0.02 to 0.87]	0,035	0.12 [0.02 to 0.88]	0,037
Positive DRE	1.23 [0.34 to 4.47]	0,754	1.03 [0.27 to 3.94]	0,968
CIPC	1.05 [1.02 to 1.08]	0,001	1.05 [1.02 to 1.08]	0,002
Testosterone, 10 ng/dl increase	0.93 [0.89 to 0.97]	0,001
Testosterone, <300 ng/dL			10.26 [3.54 to 29.76]	<0.001
AUC, [95% C.I.]	0.84 [0.77 to 0.92]		0.84 [0.73 to 0.95]
Gain in predictive accuracy; % (p-value)	6.3 (0.119)		5.9 (0.101)
	Positive margins
	Continous TT		TT≥300ng/dL TT<300ng/dL
	O.R. [95% C.I.]	p-value	O.R. [95% C.I.]	p-value
Age	0.95 [0.89 to 1.01]	0,075	0.95 [0.89 to 1.01]	0,072
PSA (ng/mL)	0.85 [0.63 to 1.15]	0,295	0.85 [0.63 to 1.14]	0,269
PSA Density, 0.1 increase	1.85 [0.5 to 6.83]	0,358	1.79 [0.49 to 6.53]	0,379
Positive DRE	0.85 [0.26 to 2.7]	0,776	0.84 [0.27 to 2.69]	0,774
CIPC	1.02 [0.99 to 1.04]	0,191	1.02 [0.99 to 1.04]	0,205
Testosterone, 10 ng/dl increase	0.98 [0.96 to 1]	0,097
Testosterone, <300 ng/dL			2.25 [0.94 to 5.43]	0,07
AUC, [95% C.I.]	0.66 [0.56 to 0.76]		0.66 [0.57 to 0.75]
Gain in predictive accuracy; % (p-value)	0.74 (0.934)		1.11 (0.904)
	Predominant Gleason 4
	Continous TT		TT≥300ng/dL TT<300ng/dL
	O.R. [95% C.I.]	p-value	O.R. [95% C.I.]	p-value
Age	1 [0.95 to 1.06]	0,996	1 [0.94 to 1.06]	0,916
PSA (ng/mL)	1.3 [0.99 to 1.71]	0,054	1.3 [0.99 to 1.71]	0,058
PSA Density, 0.1 increase	0.16 [0.05 to 0.56]	0,004	0.13 [0.04 to 0.49]	0,002
Positive DRE	0.86 [0.32 to 2.28]	0,755	0.72 [0.26 to 2.05]	0,543
CIPC	1.06 [1.04 to 1.08]	<0.001	1.06 [1.04 to 1.08]	<0.001
Testosterone, 10 ng/dl increase	0.96 [0.93 to 0.98]	<0.001
Testosterone, <300 ng/dL			6.66 [3.14 to 14.15]	<0.001
AUC, [95% C.I.]	0.81 [0.75 to 0.87]		0.82 [0.75 to 0.89]
Gain in predictive accuracy; % (p-value)	8.3 (0.046)		9.4 (0.041)

For sake of readability of the results, when treating Testosterone as continuous predictor, the Odds Ratio have been computed for a 10ng/dl increase in TT levels. Testosterone has been analyzed both as continuous and as dichotomous predictor using 300ng/dl as cut-off. CIPC: cancer involvement in positive cores; DRE: Digital rectal examination; PNI: perineural invasion; PSA: prostate-specific antigen; TT: total testosterone